About Cantai Therapeutics
Cantai Therapeutics is a private company based in Philadelpia, Pennsylvania, incorporated in 2023 in Delaware. It has reported $4,250,000 raised in three offerings on Form D since November 2023.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 15, 2026 | Jan 21, 2026 | $3,000,000fully sold | 3 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Jul 2, 2025 | Jul 15, 2025 | $550,000of $1.1M target | 3 | $183K | EquityRule 506(b) | Form D ↗ |
| Nov 6, 2023 | Nov 20, 2023amended Nov 20, 2023 | $700,000of $3.0M target | 3 | $233K | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, three offerings | $4,250,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cantai Therapeutics's Form D filed Jan 21, 2026.
RL
Ross Leimberg
Chief Operating Officer and director
EA
Errik Anderson
Executive officer
GV
Getta Vemuri
Executive officer and director
Earlier filings also listed Joshua Brandt (director, last listed Jul 2025) and Geeta Vemuri (executive officer and director, last listed Jul 2025).